Clinical Trial Detail

NCT ID NCT02989857
Title Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

cholangiocarcinoma

Therapies

Ivosidenib

Age Groups: adult senior

Additional content available in CKB BOOST